Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5901–5950 of 18646
the Company will accept David Michaels’s resignation from his position as CFO of the Company, effective immediately upon the effectiveness of the appointment of a new CFO.
On April 2, 2024, Ankur Dhingra, the principal financial officer and principal accounting officer of Summit Therapeutics Inc. (the “Company”), resigned as Chief Financial Officer of the Company.
the Company appointed its Chief Operating Officer Manmeet Soni to the office of Chief Financial Officer, in which capacity he will serve as the Company’s principal financial officer, in addition to his continuing service as Chief Operating Officer.
Mr. Pedersen notified Envela of his intent to resign as Chief Financial Officer effective March 25, 2024.
On March 19, 2024, Envela Corporation’s (the “Company”) Board of Directors elected John DeLuca, age 47, to the position of Chief Financial Officer following the resignation of current Chief Financial Officer Bret A. Pedersen.
Kwok Boon Kit was appointed as Chief Executive Officer, Treasurer and Secretary, and Director of the Company.
On April 2, 2024, Steven M. Plumb, CPA was appointed the Chief Financial Officer of the Company.
On March 31, 2024, Mike Elkin, the Chief Financial Officer of DriveItAway Holdings, Inc. (the “Company”), notified the Company that he is resigning from his position as Chief Financial Officer of the Company effective as of the close of business on March 31, 2024.
On April 2, 2024 Cambium Networks Corporation (the “Company”) announced the appointment of Jacob Sayer as Chief Financial Officer of the Company, effective the Effective Date.
On March 19, 2024, the board of directors of Pulmonx Corporation (the “Company”) appointed Mehul Joshi as the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, effective upon commencement of his employment with the Company on April 3, 2024 (the “Effective Date”).
On March 27, 2024, Erin Colgan notified Sensei Biotherapeutics, Inc. (the “Company”) of her resignation from all positions with the Company, including as Chief Financial Officer. Ms. Colgan’s resignation is voluntary and will be effective April 10, 2024, and was not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.
On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “ Company ”) Tycho Peterson submitted his resignation.
the Board of Directors of Tortoise Pipeline & Energy Fund, Inc. (the “ Company ”) appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
The appointment was made in connection with the retirement of Mr. Adams, who in addition to stepping down from his role as Chief Executive Officer of the Company retired from his position as Managing Director of Tortoise Capital Advisors, L.L.C. (the “ Adviser ”) effective as of March 31, 2024.
Effective March 31, 2024, the Board of Directors of Tortoise Midstream Energy Fund, Inc. (the “ Company ”) appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
In connection with Ms. Gengler’s transition to Chief Executive Officer, the Board of Directors appointed Sean Wickliffe to serve as Principal Financial Officer and Treasurer of the Company, also effective April 1, 2024.
Effective March 31, 2024, the Board of Directors of Tortoise Midstream Energy Fund, Inc. (the “ Company ”) appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
appointed Sean Wickliffe to serve as Principal Financial Officer and Treasurer of the Company, also effective April 1, 2024.
appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
retirement of Mr. Adams, who in addition to stepping down from his role as Chief Executive Officer of the Company retired from his position as Managing Director
The appointment was made in connection with the retirement of Mr. Adams, who in addition to stepping down from his role as Chief Executive Officer of the Company retired from his position as Managing Director of Tortoise Capital Advisors, L.L.C. (the “ Adviser ”) effective as of March 31, 2024.
In connection with Ms. Gengler’s transition to Chief Executive Officer, the Board of Directors appointed Sean Wickliffe to serve as Principal Financial Officer and Treasurer of the Company, also effective April 1, 2024.
Effective March 31, 2024, the Board of Directors of Tortoise Power and Energy Infrastructure Fund, Inc. (the “ Company ”) appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
appointed Sean Wickliffe to serve as Principal Financial Officer and Treasurer of the Company, also effective April 1, 2024.
appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
retirement of Mr. Adams, who in addition to stepping down from his role as Chief Executive Officer of the Company retired from his position as Managing Director of Tortoise Capital Advisors, L.L.C. (the “ Adviser ”) effective as of March 31, 2024.
the Board of Directors appointed Sean Wickliffe to serve as Principal Financial Officer and Treasurer of the Company, also effective April 1, 2024.
the Board of Directors of Tortoise Energy Independence Fund, Inc. (the “ Company ”) appointed Courtney Gengler to succeed P. Bradley Adams as Chief Executive Officer of the Company, effective as of April 1, 2024.
The appointment was made in connection with the retirement of Mr. Adams, who in addition to stepping down from his role as Chief Executive Officer
Frances Scally, who had served as the Company’s Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company.
the Board of Directors of the Company (the “Board”) has designated Neil Dey, the Company’s President and Chief Executive Officer, as the Company’s the principal financial and accounting officer, in addition to serving as principal executive officer.
appointed Brendon Fischer as the Company’s interim Chief Financial Officer (“CFO”), effective April 2, 2024.
On March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024.
Effective March 29, 2024, the Board appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement of Paul Casey.
Carl A. Grimstad, the chief executive officer, Armen Yeghyazarians, the chief financial officer and chief accounting officer, Thomas C. Pritchard, general counsel, David Cronin, chief engagement officer, and Timothy Newton, chief technology officer were terminated as executive officers of the Company.
Carl A. Grimstad, the chief executive officer, Armen Yeghyazarians, the chief financial officer and chief accounting officer, Thomas C. Pritchard, general counsel, David Cronin, chief engagement officer, and Timothy Newton, chief technology officer were terminated as executive officers of the Company.
On March 26, 2024, the Company appointed Robert E. Wahlman as Chief Financial Officer and Executive Vice President of both the Company and the Bank.
On March 26, 2024, Javvis Jacobson ceased to serve as Chief Financial Officer and Executive Vice President of both the Company and the Bank but will continue to serve as Treasurer of the Bank.
In connection with Mr. Kyle’s notification, the Company has reached an agreement with Tarak Mehta to become the President and Chief Executive Officer of the Company on September 5, 2024 following the conclusion of a negotiated transition period with his current employer (the “Appointment Date”).
On March 26, 2024, Richard G. Kyle, President and Chief Executive Officer of The Timken Company (the “Company”) and member of the Company’s Board of Directors (the “Board”), notified the Company of his intention to retire from his position as President and Chief Executive Officer.
On March 29, 2024, Dynavax Technologies Corporation (the “Company”) appointed Ryan Spencer to serve in a temporary capacity as Interim Chief Financial Officer (principal financial officer) of the Company while Kelly MacDonald is on maternity leave, commencing April 1, 2024.
American National and American National Bank and Trust Company (“AMNB Bank”) entered into a separation agreement with Jeffrey Haley, President and Chief Executive Officer of American National, which provided for termination of Mr. Haley’s employment with American National and American National Bank at the Effective Time
On March 22, 2024, GCT announced that the Board of Directors of GCT had appointed Edmond Cheng as Chief Financial Officer (CFO) effective March 18, 2024.
On April 1, 2024, the Company announced its appointment of Peter Sorensen as its new Chief Financial Officer and designated him the principal financial officer of the Company, effective on the same date.
On March 28, 2024, Sanuwave Health, Inc. (the “Company”) terminated without cause its chief financial officer, Toni Rinow, effective immediately.
On April 1, 2024, Jacobs Solutions Inc. (the “Company”) announced the departure of Claudia Jaramillo, Executive Vice President, Chief Financial Officer, effective April 15, 2024 (the “Effective Date”).
The Company also announced that Kevin Berryman, age 65, currently Special Advisor to the Company’s Chief Executive Officer, has succeeded Ms. Jaramillo as the Company’s interim Chief Financial Officer, effective as of March 29, 2024.
the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.
On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.